tiprankstipranks
Newamsterdam Pharma Company N.V. (NAMS)
NASDAQ:NAMS
US Market
NAMS
NewAmsterdam Pharma Company
RESEARCH TOOLSreports
Want to see NAMS full AI Analyst Report?

NewAmsterdam Pharma Company (NAMS) Stock Forecast & Price Target

264 Followers
See the Price Targets and Ratings of:

NAMS Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
NewAmsterdam
Pharma Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

NAMS Stock 12 Month Forecast

Average Price Target

$53.29
▲(79.78% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for NewAmsterdam Pharma Company in the last 3 months. The average price target is $53.29 with a high forecast of $60.00 and a low forecast of $48.00. The average price target represents a 79.78% change from the last price of $29.64.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","61":"$61","30.25":"$30.3","40.5":"$40.5","50.75":"$50.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.285714285714285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,30.25,40.5,50.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.79,30.267692307692307,32.745384615384616,35.223076923076924,37.70076923076923,40.17846153846154,42.65615384615384,45.13384615384615,47.61153846153846,50.08923076923077,52.566923076923075,55.04461538461538,57.52230769230769,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.79,29.75120879120879,31.712417582417583,33.67362637362638,35.63483516483517,37.59604395604396,39.55725274725275,41.51846153846154,43.47967032967033,45.44087912087912,47.40208791208791,49.3632967032967,51.324505494505495,{"y":53.285714285714285,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.79,29.344615384615384,30.89923076923077,32.45384615384615,34.00846153846154,35.56307692307692,37.11769230769231,38.67230769230769,40.22692307692308,41.78153846153846,43.33615384615385,44.89076923076923,46.44538461538461,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.28,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.63,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.61,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.08,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.57,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.83,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.81,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.79,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$60.00Average Price Target$53.29Lowest Price Target$48.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on NAMS
Serge Belanger
Needham
Needham
$48
Buy
61.94%
Upside
Reiterated
08/07/26
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
Citi Analyst forecast on NAMS
Unknown Analyst
Citi
Not Ranked
Citi
$55
Buy
85.56%
Upside
Reiterated
08/06/26
Citi Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
Truist Financial Analyst forecast on NAMS
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Revolution Medicines (NASDAQ: RVMD)
H.C. Wainwright Analyst forecast on NAMS
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$52
Buy
75.44%
Upside
Reiterated
08/06/26
Pantginis Reiterates Buy on NewAmsterdam, Maintains $52 12-Month Price Target Amid Key Obicetrapib Catalysts
William Blair Analyst forecast on NAMS
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analyst Matt Phipps Maintains Buy on NewAmsterdam as PREVAIL Interim Design Bolsters Cardiovascular Efficacy Odds and Risk-Reward Profile
Stifel Nicolaus Analyst forecast on NAMS
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$50
Buy
68.69%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Solventum Corporation (SOLV)
RBC Capital Analyst forecast on NAMS
Leonid Timashev
RBC Capital
RBC Capital
$51→$50
Buy
68.69%
Upside
Reiterated
08/05/26
RBC Capital Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
BMO Capital Analyst forecast on NAMS
Conor MacKay
BMO Capital
BMO Capital
$58
Buy
95.68%
Upside
Assigned
08/05/26
BMO Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)
Piper Sandler Analyst forecast on NAMS
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$60
Buy
102.43%
Upside
Reiterated
08/04/26
Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TD Cowen Analyst forecast on NAMS
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on NAMS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$45
Buy
51.82%
Upside
Reiterated
05/07/26
Guggenheim Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Goldman Sachs Analyst forecast on NAMS
Asad Haider
Goldman Sachs
Goldman Sachs
$37→$38
Hold
28.21%
Upside
Reiterated
05/07/26
Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (NASDAQ: TMCI), NewAmsterdam Pharma Company (NASDAQ: NAMS) and LENSAR (NASDAQ: LNSR)
Wells Fargo Analyst forecast on NAMS
Yanan Zhu
Wells Fargo
Wells Fargo
$45
Buy
51.82%
Upside
Reiterated
04/02/26
NewAmsterdam Pharma Company (NAMS) Receives a Buy from Wells Fargo
Cantor Fitzgerald Analyst forecast on NAMS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$49
Buy
65.32%
Upside
Reiterated
02/19/26
Cantor Fitzgerald Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham Analyst forecast on NAMS
Serge Belanger
Needham
Needham
$48
Buy
61.94%
Upside
Reiterated
08/07/26
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
Citi Analyst forecast on NAMS
Unknown Analyst
Citi
Not Ranked
Citi
$55
Buy
85.56%
Upside
Reiterated
08/06/26
Citi Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
Truist Financial Analyst forecast on NAMS
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), NewAmsterdam Pharma Company (NASDAQ: NAMS) and Revolution Medicines (NASDAQ: RVMD)
H.C. Wainwright Analyst forecast on NAMS
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$52
Buy
75.44%
Upside
Reiterated
08/06/26
Pantginis Reiterates Buy on NewAmsterdam, Maintains $52 12-Month Price Target Amid Key Obicetrapib Catalysts
William Blair Analyst forecast on NAMS
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analyst Matt Phipps Maintains Buy on NewAmsterdam as PREVAIL Interim Design Bolsters Cardiovascular Efficacy Odds and Risk-Reward Profile
Stifel Nicolaus Analyst forecast on NAMS
James Condulis
Stifel Nicolaus
Stifel Nicolaus
$50
Buy
68.69%
Upside
Reiterated
08/06/26
Analysts' Top Healthcare Picks: Enliven Therapeutics (ELVN), Solventum Corporation (SOLV)
RBC Capital Analyst forecast on NAMS
Leonid Timashev
RBC Capital
RBC Capital
$51→$50
Buy
68.69%
Upside
Reiterated
08/05/26
RBC Capital Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
BMO Capital Analyst forecast on NAMS
Conor MacKay
BMO Capital
BMO Capital
$58
Buy
95.68%
Upside
Assigned
08/05/26
BMO Capital Remains a Buy on NewAmsterdam Pharma Company (NAMS)
Piper Sandler Analyst forecast on NAMS
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$60
Buy
102.43%
Upside
Reiterated
08/04/26
Piper Sandler Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TD Cowen Analyst forecast on NAMS
Tyler Van Buren
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on NAMS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$45
Buy
51.82%
Upside
Reiterated
05/07/26
Guggenheim Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
Goldman Sachs Analyst forecast on NAMS
Asad Haider
Goldman Sachs
Goldman Sachs
$37→$38
Hold
28.21%
Upside
Reiterated
05/07/26
Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (NASDAQ: TMCI), NewAmsterdam Pharma Company (NASDAQ: NAMS) and LENSAR (NASDAQ: LNSR)
Wells Fargo Analyst forecast on NAMS
Yanan Zhu
Wells Fargo
Wells Fargo
$45
Buy
51.82%
Upside
Reiterated
04/02/26
NewAmsterdam Pharma Company (NAMS) Receives a Buy from Wells Fargo
Cantor Fitzgerald Analyst forecast on NAMS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$49
Buy
65.32%
Upside
Reiterated
02/19/26
Cantor Fitzgerald Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
ACRVAcrivon Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering NewAmsterdam Pharma Company

3 Months
Tyler Van BurenTD Cowen
Success Rate
7/12 ratings generated profit
58%
Average Return
+10.42%
Copying Tyler Van Buren's trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +10.42% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
9/12 ratings generated profit
75%
Average Return
+27.92%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +27.92% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
10/12 ratings generated profit
83%
Average Return
+32.89%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +32.89% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NAMS Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
2
4
4
9
13
Buy
10
8
7
6
3
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
13
12
16
16
In the current month, NAMS has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NAMS average Analyst price target in the past 3 months is 53.29.
Each month's total comprises the sum of three months' worth of ratings.

NAMS Financial Forecast

NAMS Earnings Forecast

Next quarter’s earnings estimate for NAMS is -$0.49 with a range of -$0.62 to -$0.33. The previous quarter’s EPS was -$0.52. NAMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NAMS has Performed in-line its overall industry.
Next quarter’s earnings estimate for NAMS is -$0.49 with a range of -$0.62 to -$0.33. The previous quarter’s EPS was -$0.52. NAMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year NAMS has Performed in-line its overall industry.

NAMS Sales Forecast

Next quarter’s sales forecast for NAMS is $7.54M with a range of $0.00 to $24.50M. The previous quarter’s sales results were $3.70M. NAMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NAMS has Performed in-line its overall industry.
Next quarter’s sales forecast for NAMS is $7.54M with a range of $0.00 to $24.50M. The previous quarter’s sales results were $3.70M. NAMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year NAMS has Performed in-line its overall industry.

NAMS Stock Forecast FAQ

What is NAMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Newamsterdam Pharma Company N.V.’s 12-month average price target is 53.29.
    What is NAMS’s upside potential, based on the analysts’ average price target?
    Newamsterdam Pharma Company N.V. has 79.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is NAMS a Buy, Sell or Hold?
          Newamsterdam Pharma Company N.V. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Newamsterdam Pharma Company N.V.’s price target?
            The average price target for Newamsterdam Pharma Company N.V. is 53.29. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $60.00 ,the lowest forecast is $48.00. The average price target represents 79.78% Increase from the current price of $29.64.
              What do analysts say about Newamsterdam Pharma Company N.V.?
              Newamsterdam Pharma Company N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of NAMS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.